A Feasibility Study of Neoadjuvant XELOX Without Radiotherapy for Locally Advanced Lower Rectal Cancer

Takashi Ueki, Tatsuya Manabe, Shigetaka Inoue, Jun Ienaga, Naoki Yamanaka, Takuya Egami, Mikimasa Ishikawa, Hiroyuki Konomi, Akashi Ikubo, Kinuko Nagayoshi, Masafumi Nakamura, Masao Tanaka

研究成果: ジャーナルへの寄稿記事

4 引用 (Scopus)

抄録

AIM: This study was planned to evaluate the efficacy and safety of preoperative capecitabine and oxaliplatin (XELOX) without radiation in patients with locally advanced lower rectal cancer.

PATIENTS AND METHODS: Patients with clinical stage II/III lower rectal cancer underwent three cycles of XELOX followed by radical surgery. The primary end-point was the R0 resection rate.

RESULTS: Thirty-one patients were recruited between February 2012 and August 2014. The completion rate of neoadjuvant chemotherapy was 96.5% among the 29 patients who received it; the remaining two refused chemotherapy and underwent immediate surgery. Grade 3-4 adverse events occurred in nine patients (31%). All 29 patients who received chemotherapy underwent radical resection. The R0 resection rate was 96.5% among these 29 patients. Pathological complete responses were achieved in three patients (10.3%) and downstaging occurred in 13 (44.8%).

CONCLUSION: This pilot study found that neoadjuvant XELOX for locally advanced lower rectal cancer is feasible and safe. This neoadjuvant treatment improved resection margin status.

元の言語英語
ページ(範囲)741-747
ページ数7
ジャーナルAnticancer research
36
発行部数2
出版物ステータス出版済み - 2 1 2016

Fingerprint

Feasibility Studies
Rectal Neoplasms
Radiotherapy
oxaliplatin
Drug Therapy
Neoadjuvant Therapy
XELOX
Radiation
Safety

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

これを引用

Ueki, T., Manabe, T., Inoue, S., Ienaga, J., Yamanaka, N., Egami, T., ... Tanaka, M. (2016). A Feasibility Study of Neoadjuvant XELOX Without Radiotherapy for Locally Advanced Lower Rectal Cancer. Anticancer research, 36(2), 741-747.

A Feasibility Study of Neoadjuvant XELOX Without Radiotherapy for Locally Advanced Lower Rectal Cancer. / Ueki, Takashi; Manabe, Tatsuya; Inoue, Shigetaka; Ienaga, Jun; Yamanaka, Naoki; Egami, Takuya; Ishikawa, Mikimasa; Konomi, Hiroyuki; Ikubo, Akashi; Nagayoshi, Kinuko; Nakamura, Masafumi; Tanaka, Masao.

:: Anticancer research, 巻 36, 番号 2, 01.02.2016, p. 741-747.

研究成果: ジャーナルへの寄稿記事

Ueki, T, Manabe, T, Inoue, S, Ienaga, J, Yamanaka, N, Egami, T, Ishikawa, M, Konomi, H, Ikubo, A, Nagayoshi, K, Nakamura, M & Tanaka, M 2016, 'A Feasibility Study of Neoadjuvant XELOX Without Radiotherapy for Locally Advanced Lower Rectal Cancer', Anticancer research, 巻. 36, 番号 2, pp. 741-747.
Ueki T, Manabe T, Inoue S, Ienaga J, Yamanaka N, Egami T その他. A Feasibility Study of Neoadjuvant XELOX Without Radiotherapy for Locally Advanced Lower Rectal Cancer. Anticancer research. 2016 2 1;36(2):741-747.
Ueki, Takashi ; Manabe, Tatsuya ; Inoue, Shigetaka ; Ienaga, Jun ; Yamanaka, Naoki ; Egami, Takuya ; Ishikawa, Mikimasa ; Konomi, Hiroyuki ; Ikubo, Akashi ; Nagayoshi, Kinuko ; Nakamura, Masafumi ; Tanaka, Masao. / A Feasibility Study of Neoadjuvant XELOX Without Radiotherapy for Locally Advanced Lower Rectal Cancer. :: Anticancer research. 2016 ; 巻 36, 番号 2. pp. 741-747.
@article{2cdc044d5fcd4ba1913476b08e365edb,
title = "A Feasibility Study of Neoadjuvant XELOX Without Radiotherapy for Locally Advanced Lower Rectal Cancer",
abstract = "AIM: This study was planned to evaluate the efficacy and safety of preoperative capecitabine and oxaliplatin (XELOX) without radiation in patients with locally advanced lower rectal cancer.PATIENTS AND METHODS: Patients with clinical stage II/III lower rectal cancer underwent three cycles of XELOX followed by radical surgery. The primary end-point was the R0 resection rate.RESULTS: Thirty-one patients were recruited between February 2012 and August 2014. The completion rate of neoadjuvant chemotherapy was 96.5{\%} among the 29 patients who received it; the remaining two refused chemotherapy and underwent immediate surgery. Grade 3-4 adverse events occurred in nine patients (31{\%}). All 29 patients who received chemotherapy underwent radical resection. The R0 resection rate was 96.5{\%} among these 29 patients. Pathological complete responses were achieved in three patients (10.3{\%}) and downstaging occurred in 13 (44.8{\%}).CONCLUSION: This pilot study found that neoadjuvant XELOX for locally advanced lower rectal cancer is feasible and safe. This neoadjuvant treatment improved resection margin status.",
author = "Takashi Ueki and Tatsuya Manabe and Shigetaka Inoue and Jun Ienaga and Naoki Yamanaka and Takuya Egami and Mikimasa Ishikawa and Hiroyuki Konomi and Akashi Ikubo and Kinuko Nagayoshi and Masafumi Nakamura and Masao Tanaka",
year = "2016",
month = "2",
day = "1",
language = "English",
volume = "36",
pages = "741--747",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "2",

}

TY - JOUR

T1 - A Feasibility Study of Neoadjuvant XELOX Without Radiotherapy for Locally Advanced Lower Rectal Cancer

AU - Ueki, Takashi

AU - Manabe, Tatsuya

AU - Inoue, Shigetaka

AU - Ienaga, Jun

AU - Yamanaka, Naoki

AU - Egami, Takuya

AU - Ishikawa, Mikimasa

AU - Konomi, Hiroyuki

AU - Ikubo, Akashi

AU - Nagayoshi, Kinuko

AU - Nakamura, Masafumi

AU - Tanaka, Masao

PY - 2016/2/1

Y1 - 2016/2/1

N2 - AIM: This study was planned to evaluate the efficacy and safety of preoperative capecitabine and oxaliplatin (XELOX) without radiation in patients with locally advanced lower rectal cancer.PATIENTS AND METHODS: Patients with clinical stage II/III lower rectal cancer underwent three cycles of XELOX followed by radical surgery. The primary end-point was the R0 resection rate.RESULTS: Thirty-one patients were recruited between February 2012 and August 2014. The completion rate of neoadjuvant chemotherapy was 96.5% among the 29 patients who received it; the remaining two refused chemotherapy and underwent immediate surgery. Grade 3-4 adverse events occurred in nine patients (31%). All 29 patients who received chemotherapy underwent radical resection. The R0 resection rate was 96.5% among these 29 patients. Pathological complete responses were achieved in three patients (10.3%) and downstaging occurred in 13 (44.8%).CONCLUSION: This pilot study found that neoadjuvant XELOX for locally advanced lower rectal cancer is feasible and safe. This neoadjuvant treatment improved resection margin status.

AB - AIM: This study was planned to evaluate the efficacy and safety of preoperative capecitabine and oxaliplatin (XELOX) without radiation in patients with locally advanced lower rectal cancer.PATIENTS AND METHODS: Patients with clinical stage II/III lower rectal cancer underwent three cycles of XELOX followed by radical surgery. The primary end-point was the R0 resection rate.RESULTS: Thirty-one patients were recruited between February 2012 and August 2014. The completion rate of neoadjuvant chemotherapy was 96.5% among the 29 patients who received it; the remaining two refused chemotherapy and underwent immediate surgery. Grade 3-4 adverse events occurred in nine patients (31%). All 29 patients who received chemotherapy underwent radical resection. The R0 resection rate was 96.5% among these 29 patients. Pathological complete responses were achieved in three patients (10.3%) and downstaging occurred in 13 (44.8%).CONCLUSION: This pilot study found that neoadjuvant XELOX for locally advanced lower rectal cancer is feasible and safe. This neoadjuvant treatment improved resection margin status.

UR - http://www.scopus.com/inward/record.url?scp=84979831187&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84979831187&partnerID=8YFLogxK

M3 - Article

C2 - 26851033

AN - SCOPUS:84979831187

VL - 36

SP - 741

EP - 747

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 2

ER -